AbbVie seeks EMA approval for Skyrizi subcutaneous use in Crohn's
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Nasdaq, S&P 500 climb ahead of keenly awaited Fed decision
- Oil slips as Saudi Arabia offers more crude via Oman; diesel near record high
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Stocks tend to rise after the Fed starts to hike
- Raymond James Downgrades Ascendis Pharma (ASND) to Outperform
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
August 27, 2026 2:00 AM EDTSubmission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV) induction
NORTH CHICAGO, Ill., Aug. 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the... More
